



**Supplementary Table S1.** Patient characteristics for the entire study cohort.

	Percentage	
<b>n</b>	2384	100
<b>Age</b>	59.0 ± 12.8	
<b>Menopausal status</b>		
Premenopausal	750	31.5
Postmenopausal	1575	66.1
Male	3	0.1
n/a	56	2.3
<b>Histology</b>		
NST	1951	81.8
ILC	301	12.6
Other	127	5.3
n/a	5	0.2
<b>Grading</b>		
1	214	9.0
2	1470	61.7
3	694	29.1
n/a	6	0.3
<b>T-stage</b>	0	
0	272	11.4
1	1315	55.2
2	657	27.6
3	97	4.1
4	43	1.8
<b>N-stage</b>		
0	1712	71.8
1	513	21.5
2	112	4.7
3	46	1.9
X	1	0.0
<b>ER status</b>		
+	1971	82.7
-	413	17.3
<b>PR status</b>		
+	1614	67.7
-	770	32.3
<b>HER2 status</b>		
+	345	14.5
-	2039	85.5
<b>Ki67</b>		
≥ 20 %	1126	47.2
< 20 %	1258	52.8
<b>Chemotherapy</b>		
Neoadjuvant	505	21.2
Adjuvant	507	21.3
None	1372	57.6

NST, non-special type; ILC, invasive lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer; n/a, not available.